An oncogenic role for A20 is suggested by the increased A20 expression in some cancers: A20 is elevated in undifferentiated nasopharyngeal carcinoma [40], poorly differentiated head and neck cancers [40], gliomas [41], and inflammatory breast cancer [42]. Here, TNFAIP3 is linked to inflammatory breast carcinoma.